Composition of Certain Financial Statement Captions (Tables)

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Composition of Certain Financial Statement Captions

	For the years ended December 31,
(In thousands)	2018			2017
Accounts receivable, net
Accounts receivable	$	145,665		$	166,962
Less: allowance for doubtful accounts	(1,758		)	(1,446		)
	$	143,907		$	165,516
Inventories, net
Consumable supplies	$	23,264		$	21,546
Finished products	15,259			21,012
Work in-process	2,473			5,873
Raw materials	4,259			7,467
Less: inventory reserve	(2,956		)	(6,565		)
	$	42,299		$	49,333
Other current assets and prepaid expenses
Other receivables	$	2,368		$	3,398
Taxes recoverable	15,708			18,138
Prepaid supplies	9,693			8,207
Prepaid insurance	3,436			3,532
Other	3,847			9,238
	$	35,052		$	42,513
Property, plant and equipment, net:
Machinery, medical and other equipment	$	147,757		$	112,961
Leasehold improvements	34,607			34,121
Furniture and fixtures	12,737			11,540
Automobiles and aircraft	10,133			11,137
Software	13,425			12,469
Building	18,554			8,227
Land	2,453			2,552
Construction in process	16,670			39,397
Less: accumulated depreciation	(111,662		)	(85,847		)
	$	144,674		$	146,557
Intangible assets, net:
Customer relationships	$	446,296		$	448,345
Technologies	340,729			340,921
Trade names	50,404			50,553
Covenants not to compete	16,322			16,372
Licenses	5,766			10,305
Product registrations	7,861			10,475
Other	5,613			5,799
Less: accumulated amortization	(258,539		)	(198,935		)
	$	614,452		$	683,835

	For the years ended December 31,
(In thousands)	2018		2017
Accrued expenses:
Contract liabilities	$	63,503	$	56,883
Employee benefits	45,621		50,377
Taxes payable	3,233		4,609
Contingent consideration	2,375		11,750
Clinical trials	10,401		12,191
Capital leases short-term	3,280		3,399
Milestone payment	4,871		4,868
Professional fees	7,935		2,355
Other	62,294		79,364
	$	203,513	$	225,796
Other long-term liabilities:
Contract liabilities	$	27,566	$	95,450
Line of credit	105,198		104,152
Contingent consideration	22,162		29,603
Capital leases long-term	5,620		7,786
Mortgages and other debts payable	4,654		1,567
Other	33,768		17,857
	$	198,968	$	256,415

Summary of Valuation Allowance

The following table reflects the changes in the allowance for doubtful accounts, provision for inventory reserve and tax valuation allowance accounts:

(In thousands)	Beginning balance			Charged to expense		Written-off		Charged to other		Ending balance
2018
Allowance for doubtful accounts	$	(1,446	)	(665	)	353		—		$	(1,758	)
Inventory reserve	$	(6,565	)	(1,915	)	5,524		—		$	(2,956	)
Tax valuation allowance	$	(142,062	)	(12,854	)	—		—		$	(154,916	)
2017
Allowance for doubtful accounts	$	(1,671	)	(891	)	1,063		53		$	(1,446	)
Inventory reserve	$	(945	)	(5,390	)	(230	)	—		$	(6,565	)
Tax valuation allowance	$	(55,415	)	(82,358	)	—		(4,289	)	$	(142,062	)

Schedule of Goodwill

The following table summarizes the changes in Goodwill during the years ended December 31, 2018 and 2017.

	2018										2017
(In thousands)	Balance at January 1		Goodwill impairment			Foreign exchange and other			Balance at December 31st		Balance at January 1		Foreign exchange		Balance at December 31
Pharmaceuticals
CURNA	$	4,827				$	—		$	4,827	$	4,827	$	—	$	4,827
EirGen	89,226					(3,981		)	85,245		78,358		10,868		89,226
FineTech	11,698		(11,698		)	—			—		11,698		—		11,698
OPKO Biologics	139,784					—			139,784		139,784		—		139,784
OPKO Chile	5,203					(589		)	4,614		4,785		418		5,203
OPKO Health Europe	7,898					(352		)	7,546		6,936		962		7,898
OPKO Renal	2,069					—			2,069		2,069		—		2,069
Transition Therapeutics	3,608					(286		)	3,322		3,360		248		3,608
Diagnostics
BioReference	401,821					—			401,821		401,821		—		401,821
OPKO Diagnostics	17,977					—			17,977		17,977		—		17,977
OPKO Lab	32,988					—			32,988		32,988		—		32,988
	$	717,099	$	(11,698	)	$	(5,208	)	$	700,193	$	704,603	$	12,496	$	717,099